Biologic Failure and Elective Colectomy Outcomes in UC

Key Takeaways

• Among patients with ulcerative colitis undergoing elective subtotal colectomy with end ileostomy, postoperative complications did not differ significantly after fewer versus more biologic failures.
• Venous thromboembolism and progression to second-stage pouch surgery showed no significant differences between the groups.
• The lower-failure group included a substantially higher proportion of men, a baseline difference rather than a surgical outcome.

Investigators retrospectively reviewed elective subtotal colectomy outcomes in ulcerative colitis among patients who underwent subtotal colectomy (STC) with end ileostomy (EI) from May 2018 through January 2022. Of 98 patients who underwent STC, 53 had elective operations; emergent cases were excluded from the comparison. The elective cohort included 30 patients after 1–2 failed biologics and 23 after 3–4. Investigators collected demographics, preoperative clinical manifestations, and operative and postoperative outcomes.

Postoperative complications occurred in 10/30 (33%) patients after 1–2 failed biologics versus 7/23 (30%) after 3–4 failures (p = 0.82). This difference was not statistically significant and does not establish equivalent complication risks. Venous thromboembolism (VTE) also showed no significant between-group difference after elective STC with EI.

Progression to second-stage ileoanal pouch (IPAA) surgery occurred in 20/30 (67%) patients after 1–2 failed biologics versus 16/23 (70%) after 3–4, without a significant difference. At baseline, 25 (83%) versus 8 (35%) patients were men (p < 0.01); this was a group characteristic, not a surgical outcome. Operative approaches and operative times were similar. Hospital stay was numerically longer after 3–4 failures, but the difference was not statistically significant.

The retrospective comparison included only elective cases and involved a small cohort with a pronounced sex imbalance. The nonsignificant differences in complications, VTE, hospital stay, and pouch progression do not demonstrate equal risks, show that the number of failed biologics causes similar outcomes, or establish an optimal threshold for surgery.

The authors characterized surgical outcomes after 3–4 failed biologics as similar to those after 1–2 in this elective cohort. Their assessment concerns patients who underwent surgery, not a comparison of alternative treatment sequences.

Clinician Questions

How long after elective subtotal colectomy did patients with ulcerative colitis reach second-stage IPAA surgery?

Among patients with ulcerative colitis who underwent elective subtotal colectomy with end ileostomy, second-stage ileoanal pouch surgery occurred at 11.1 ± 4 months after 1–2 failed biologics versus 9.2 ± 2 months after 3–4 failed biologics.

Does failing two biologics establish when elective colectomy is preferable for severe ulcerative colitis?

No. The authors suggested that patients with severe ulcerative colitis and poor quality of life after two failed biologic lines might be better off electing subtotal colectomy with end ileostomy than undergoing further unsuccessful biologic trials. The retrospective elective-cohort comparison did not test whether surgery at that point improves outcomes or establish an optimal number of biologic trials.